GoodRx Holdings, Inc. Class A (GDRX)

GoodRx Holdings, Inc.'s stock price has experienced a significant decline in the past six months. As of November 21, 2025, the share price was $2.71, representing a 44.58% decrease from $4.89 on November 25, 2024. Over the last year, the stock price changed by -47.06%. The stock has also seen a -25.13% change over the last six months and a -28.35% fall in the past month. GoodRx reported its Q3 2025 earnings on November 5, 2025, posting an earnings per share (EPS) of $0.08, which exceeded analysts' expectations of $0.07 by 14.29%. Following this earnings announcement, GDRX shares declined by 1.5% the day after to close at $3.26, and subsequently drifted 18.6% lower over the next 18 days. The company's Q2 2025 earnings, reported on August 7, 2025, also beat estimates with an EPS of $0.09 against an expected $0.08. However, in Q4 2024, the company missed analyst estimates, reporting an EPS of $0.09 against an expected $0.10. Analysts have a "Buy" consensus rating for GDRX as of November 26, 2025, with 20% recommending a Strong Buy, 30% a Buy, and 50% suggesting Holding. The average one-year price target for GoodRx Holdings, Inc. is $5.22, with forecasts ranging from a low of $3.43 to a high of $7.35.

GoodRx Holdings Inc. exhibits some demand seasonality for its stock returns. Historical data suggests that buying GDRX stock in January has the highest probability of a positive return (60.00%), while November has the lowest probability (16.67%). The company's revenue growth expectations for 2024 have been revised upwards, partly supported by increased utilization from seasonal factors and strategic initiatives like retailer direct contracting.

GoodRx Holdings, Inc. is a consumer-focused digital healthcare platform that provides information and tools for consumers to compare prices and save on prescription drug purchases in the United States. The company operates a price comparison platform and offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, telehealth services through GoodRx Care, and healthcare products for pets. GoodRx was founded in 2011 and is headquartered in Santa Monica, California.

GoodRx Holdings, Inc. primarily operates within the United States and is headquartered in Santa Monica, California.

In the past year, GoodRx has focused on strategic initiatives to enhance its brand awareness and engage in policy discussions aimed at leveraging market shifts towards greater price transparency and direct-to-consumer access. The company launched a "Savings Wrangler" campaign to increase unaided awareness and GoodRx search volumes. GoodRx has also expanded access and affordability programs with pharmaceutical manufacturers like Novo Nordisk and Amgen, and strengthened retail partnerships, such as the RxSmartSaver counter solution launch at Kroger. These efforts are expected to be advantageous for the company's growth. No specific events negatively impacting GoodRx's brand reputation in the past year were found in the provided search results.

GoodRx Holdings, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. Major institutional holders include Francisco Partners Management, LP, Vanguard Group Inc, Rubric Capital Management LP, Lakewood Capital Management, LP, and Ameriprise Financial Inc. Abdiel Capital Management LLC is the largest individual shareholder. Institutional ownership in GoodRx Holdings, Inc. stands at 128.28% as of April 16, 2025, with a total of 120,755,412 shares held by 264 institutional owners. Insider ownership is approximately 4.53%.